3 Reasons to Buy This Dividend King After Its Steep Sell-Off

Key Points Abbott's stock plunged after the company reported lower-than-expected Q4 revenue last week. However, Abbott's revenue growth should accelerate in 2026. The healthcare giant also expects to close a game-changing acquisition in the second quarter of this year. 10 stocks we like better than Abbott Laboratories › Abbott Laboratories (NYSE: ABT) announced its 2025 fourth-quarter and full-year results before the market opened on Thursday, Jan. 22, 2026. And its shares promptly plunged nearly ...